| Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases K Papamichael, AS Cheifetz, GY Melmed, PM Irving, NV Casteele, ... Clinical Gastroenterology and Hepatology 17 (9), 1655-1668. e3, 2019 | 337 | 2019 |
| Depression is associated with more aggressive inflammatory bowel disease B Kochar, EL Barnes, MD Long, KC Cushing, J Galanko, CF Martin, ... Official journal of the American College of Gastroenterology| ACG 113 (1), 80-85, 2018 | 175 | 2018 |
| Results at up to 30 years after ileal pouch–anal anastomosis for chronic ulcerative colitis AL Lightner, KL Mathis, EJ Dozois, D Hahnsloser, EV Loftus Jr, LE Raffals, ... Inflammatory bowel diseases 23 (5), 781-790, 2017 | 171 | 2017 |
| A gene-targeted approach to investigate the intestinal butyrate-producing bacterialcommunity M Vital, CR Penton, Q Wang, VB Young, DA Antonopoulos, ML Sogin, ... Microbiome 1, 1-14, 2013 | 170 | 2013 |
| Effects of concomitant immunomodulator therapy on efficacy and safety of anti–tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials JL Jones, GG Kaplan, L Peyrin-Biroulet, L Baidoo, S Devlin, GY Melmed, ... Clinical Gastroenterology and Hepatology 13 (13), 2233-2240. e2, 2015 | 138 | 2015 |
| Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease AL Lightner, LE Raffals, KL Mathis, RR Cima, CS Tse, JH Pemberton, ... Journal of Crohn's and Colitis 11 (2), 185-190, 2017 | 129 | 2017 |
| Predictors of health-related quality of life and adherence in Crohn’s disease and ulcerative colitis: implications for clinical management A Tabibian, JH Tabibian, LJ Beckman, LL Raffals, KA Papadakis, ... Digestive diseases and sciences 60, 1366-1374, 2015 | 113 | 2015 |
| Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects SM Huse, VB Young, HG Morrison, DA Antonopoulos, J Kwon, S Dalal, ... Microbiome 2, 1-8, 2014 | 104 | 2014 |
| Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease AL Lightner, NP McKenna, CS Tse, N Hyman, R Smith, G Ovsepyan, ... Journal of Crohn's and Colitis 12 (4), 402-407, 2018 | 101 | 2018 |
| An increased abundance of Clostridiaceae characterizes arthritis in inflammatory bowel disease and rheumatoid arthritis: a cross-sectional study DA Muņiz Pedrogo, J Chen, B Hillmann, P Jeraldo, G Al-Ghalith, V Taneja, ... Inflammatory bowel diseases 25 (5), 902-913, 2019 | 99 | 2019 |
| The microbiome in Crohn's disease: role in pathogenesis and role of microbiome replacement therapies S Khanna, LE Raffals Gastroenterology Clinics 46 (3), 481-492, 2017 | 94 | 2017 |
| Ustekinumab is effective for the treatment of Crohn’s disease of the pouch in a multicenter cohort KN Weaver, M Gregory, G Syal, P Hoversten, SB Hicks, D Patel, ... Inflammatory bowel diseases 25 (4), 767-774, 2019 | 86 | 2019 |
| Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center L Kwapisz, LE Raffals, DH Bruining, DS Pardi, WJ Tremaine, SV Kane, ... Clinical Gastroenterology and Hepatology 19 (3), 616-617, 2021 | 82 | 2021 |
| Crohn's disease of the esophagus: clinical features and treatment outcomes in the biologic era KM De Felice, DA Katzka, LE Raffals Inflammatory bowel diseases 21 (9), 2106-2113, 2015 | 75 | 2015 |
| Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease CS Tse, EV Loftus Jr, LE Raffals, AA Gossard, AL Lightner Alimentary pharmacology & therapeutics 48 (2), 190-195, 2018 | 74 | 2018 |
| Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: a population-based case-control study S Aniwan, WJ Tremaine, LE Raffals, SV Kane, EV Loftus Jr Journal of Crohn's and Colitis 12 (2), 137-144, 2018 | 74 | 2018 |
| Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a multicenter US cohort M Gregory, KN Weaver, P Hoversten, SB Hicks, D Patel, MA Ciorba, ... Inflammatory bowel diseases 25 (9), 1569-1576, 2019 | 73 | 2019 |
| Tuberculosis of the gastrointestinal tract and associated viscera T Malikowski, M Mahmood, T Smyrk, L Raffals, V Nehra Journal of clinical tuberculosis and other mycobacterial diseases 12, 1-8, 2018 | 73 | 2018 |
| Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized … PS Dulai, JC Buckey Jr, LE Raffals, JM Swoger, PL Claus, K O'Toole, ... Official journal of the American College of Gastroenterology| ACG 113 (10 …, 2018 | 72 | 2018 |
| Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations AL Lightner, NP McKenna, CS Tse, LE Raffals, EV Loftus Jr, KL Mathis Alimentary pharmacology & therapeutics 47 (5), 573-580, 2018 | 71 | 2018 |
